Take­da gets Japan­ese an­titrust reg­u­la­tors' bless­ing for Shire deal; France's Ac­ti­cor Biotech rais­es €15.3M for stroke drug

Take­da has cleared an­oth­er hur­dle for the Shire buy­out that would make it one of the world’s 10 biggest phar­ma com­pa­nies. The fair trade com­mis­sion in Japan — Take­da’s an­ces­tral home — has grant­ed “un­con­di­tion­al clear­ance” for the ac­qui­si­tion, join­ing an­titrust reg­u­la­tors in the US, Chi­na and Brazil. The EU has yet to give its fi­nal de­ci­sion, which is ex­pect­ed in No­vem­ber. “Take­da is proud of its Japan­ese her­itage, and we are look­ing for­ward to build­ing on this her­itage as a com­bined com­pa­ny to con­tin­ue de­liv­er­ing high­ly-in­no­v­a­tive med­i­cines that are trans­for­ma­tive to pa­tients in Japan and around the world,” said CEO Christophe We­ber, whose glob­al­iza­tion strat­e­gy has been meet­ing some high-pro­file push­back from tra­di­tion­al­ists at the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.